Skip to main content
. Author manuscript; available in PMC: 2019 Nov 2.
Published in final edited form as: Lancet HIV. 2019 Sep 27;6(11):e800–e806. doi: 10.1016/S2352-3018(19)30227-9

Figure 1. Person Years of Follow-Up in Three HIV PrEP Trials.

Figure 1

Note:

iPrEx: TDF/FTC v. placebo superiority study
HPTN083: TDF/FTC v. Injectable cabotegravir non-inferiority study
DISCOVER: TDF/FTC v. TAF/FTC non-inferiority study

TDF/FTC: tenofovir disoproxil fumarate and emtricitabine

TAF/FTC: tenofovir alafenamide with emtricitabine